April 30, 2020 / 7:07 PM / 24 days ago

BRIEF-Genmab Says CHMP Issues Positive Opinion Recommending Subcutaneous Formulation Of Daratumumab For The Treatment Of Patients With Multiple Myeloma

April 30 (Reuters) - Genmab A/S:

* REG-CHMP ISSUES POSITIVE OPINION RECOMMENDING SUBCUTANEOUS FORMULATION OF DARATUMUMAB FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

* GENMAB A/S - OPINION BASED ON DATA FROM PHASE III COLUMBA AND PHASE II PLEIADES STUDIES COPENHAGEN, DENMARK Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below